NCT00230477

Brief Summary

This project is a randomized, open-label trial of adefovir dipivoxil (Hepsera) and lamivudine combination therapy versus adefovir dipivoxil (Hepsera) monotherapy. Both adefovir dipivoxil and lamivudine are nucleoside analogues approved by the U.S. FDA for the treatment of chronic hepatitis B. The primary hypothesis is that subjects treated with combination therapy will see their viral DNA count decrease in an amount greater than subjects treated with monotherapy. The secondary hypothesis is that subjects treated with combination therapy will have a higher HBeAg conversion rate compared to historical controls of subjects treated with lamivudine or adefovir dipivoxil monotherapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Apr 2003

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2003

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
18 days until next milestone

First Posted

Study publicly available on registry

September 30, 2005

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2007

Completed
Last Updated

November 15, 2007

Status Verified

November 1, 2007

First QC Date

September 12, 2005

Last Update Submit

November 14, 2007

Conditions

Hepatitis B

Keywords

Hepatitis B

Outcome Measures

Primary Outcomes (1)

  • Subjects treated with combination therapy will have a decrease in the viral DNA that is greater than the subjects treated with monotherapy.

    one year

Secondary Outcomes (1)

  • Subjects treated with combination therapy will have an improved HBeAg conversion rate compared to historical controls treated with either lamivudine or adefovir dipivoxil monotherapy.

    one year

Study Arms (2)

Mono therapy

ACTIVE COMPARATOR

Hepsera

Drug: Hepsera

Combo therapy

ACTIVE COMPARATOR
Drug: Hepsera and lamivudine

Interventions

HepseraDRUG
Mono therapy
Hepsera and lamivudineDRUG
Combo therapy

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • older than 18 years
  • HBsAg+ at screening and for at least 6 months prior to study entry
  • HBeAg+
  • HBV DNA greater than 6 log10 copies/mL
  • Platelet count greater than 50,000 platelets/mm3
  • Hemoglobin greater than 7.5 g/dL
  • ALT less than ULN
  • Estimated creatine clearance\>50 mL/min as estimated by the Crockcroft-Gault equation ((140-age) x (kg)/(serum creatine x 72) (for women x 0.85))
  • Female and male participants must be practicing an effective form of contraception (male or female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, hormonal contraception)
  • Serum alpha-fetoprotein less than 50 ng/mL within 30 days of study entry
  • Childs-Pugh score less than 7 and no ascites, variceal bleeding, or hepatic encephalopathy
  • able to give written informed consent and to comply with the study protocol

You may not qualify if:

  • history or evidence of HIV, hepatitis C or hepatitis D
  • known or suspected hypersensitivity to adefovir or other nucleoside/nucleotide analogs.
  • history of clinically significant renal dysfunction
  • any active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol
  • pregnancy or breastfeeding
  • receipt of systemic corticosteroids within 90 days of study entry
  • receipt of nephrotoxic drugs within 8 weeks prior to study screening or expected use of these agents during the course of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Harborview Medical Center

Seattle, Washington, 98104, United States

Location

MeSH Terms

Conditions

Hepatitis B

Interventions

adefovir dipivoxilLamivudine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitisLiver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

ZalcitabineDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesDideoxynucleosides

Study Officials

  • John D Scott, MD, MS

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 30, 2005

Study Start

April 1, 2003

Study Completion

August 1, 2007

Last Updated

November 15, 2007

Record last verified: 2007-11

Locations

US(1)